去勢抵抗性前立腺がん（CRPC）/ HRPCA治療の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D005-00161 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール • 産業分類：医療・製薬

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、去勢抵抗性前立腺がん（CRPC）/ HRPCA治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。去勢抵抗性前立腺がん（CRPC）/ HRPCA治療の種類別市場規模（経口療法、注射療法）、用途別市場規模（病院、診療所、自宅設定、外来手術センター（ASC））、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Astellas Inc.、Dendreon Corporation、Johnson & Johnson、Sanofi S.A、Bayer AG ・地域別グローバル市場分析 2015年-2020年 ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療の北米市場（アメリカ、カナダ、メキシコ） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療の南米市場（ブラジル、アルゼンチン） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：経口療法、注射療法 ・用途別分析：病院、診療所、自宅設定、外来手術センター（ASC） ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.9% in the forecast period of 2020 to 2025 and will expected to reach USD 9300.5 million by 2025, from USD 7669.7 million in 2019.

The Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market has been segmented into:
Oral Therapy
Injectable Therapy

By Application, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics has been segmented into:
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share Analysis
Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics are:
Astellas Inc.
Dendreon Corporation
Johnson & Johnson
Sanofi S.A
Bayer AG

レポート目次

---

Table of Contents

1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Overview
1.1 Product Overview and Scope of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics
1.2 Classification of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Type
1.2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type in 2019
1.2.3 Oral Therapy
1.2.4 Injectable Therapy
1.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market by Application
1.3.1 Overview: Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals & Clinics
1.3.3 Home Settings
1.3.4 Ambulatory Surgical Centers (ASCs)
1.4 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market by Regions
1.4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Astellas Inc.
2.1.1 Astellas Inc. Details
2.1.2 Astellas Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Astellas Inc. SWOT Analysis
2.1.4 Astellas Inc. Product and Services
2.1.5 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Dendreon Corporation
2.2.1 Dendreon Corporation Details
2.2.2 Dendreon Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Dendreon Corporation SWOT Analysis
2.2.4 Dendreon Corporation Product and Services
2.2.5 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Johnson & Johnson SWOT Analysis
2.3.4 Johnson & Johnson Product and Services
2.3.5 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Sanofi S.A
2.4.1 Sanofi S.A Details
2.4.2 Sanofi S.A Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Sanofi S.A SWOT Analysis
2.4.4 Sanofi S.A Product and Services
2.4.5 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Bayer AG
2.5.1 Bayer AG Details
2.5.2 Bayer AG Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Bayer AG SWOT Analysis
2.5.4 Bayer AG Product and Services
2.5.5 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Market Share
3.2.2 Top 10 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Market Share by Regions
4.2 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries
5.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries (2015-2020)
5.2 USA Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries
6.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries
7.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries (2015-2020)
7.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries
8.1 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Countries
9.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast by Type (2019-2024)
10.3 Oral Therapy Revenue Growth Rate (2015-2025)
10.4 Injectable Therapy Revenue Growth Rate (2015-2025)
11 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment by Application
11.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospitals & Clinics Revenue Growth (2015-2020)
11.4 Home Settings Revenue Growth (2015-2020)
11.5 Ambulatory Surgical Centers (ASCs) Revenue Growth (2015-2020)
12 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Forecast (2021-2025)
12.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Forecast (2021-2025)
12.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Astellas Inc. Corporate Information, Location and Competitors
Table 6. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Business
Table 7. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Astellas Inc. SWOT Analysis
Table 9. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 10. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Dendreon Corporation Corporate Information, Location and Competitors
Table 12. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Business
Table 13. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Dendreon Corporation SWOT Analysis
Table 15. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 16. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Johnson & Johnson Corporate Information, Location and Competitors
Table 18. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Business
Table 19. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Johnson & Johnson SWOT Analysis
Table 21. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 22. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Sanofi S.A Corporate Information, Location and Competitors
Table 24. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Business
Table 25. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Sanofi S.A SWOT Analysis
Table 27. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 28. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Bayer AG Corporate Information, Location and Competitors
Table 30. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Business
Table 31. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Bayer AG SWOT Analysis
Table 33. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 34. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 36. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Players (2015-2020)
Table 37. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 38. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Regions (2015-2020)
Table 39. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries (2015-2020)
Table 40. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries (2015-2020)
Table 41. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 42. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 43. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Countries (2015-2020)
Table 44. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries (2015-2020)
Table 45. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 46. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries (2015-2020)
Table 47. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 48. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Type (2015-2020)
Table 49. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Forecast by Type (2021-2025)
Table 50. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2015-2020)
Table 51. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Application (2015-2020)
Table 52. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Forecast by Application (2021-2025)
Table 53. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Picture
Figure 2. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type in 2019
Figure 3. Oral Therapy Picture
Figure 4. Injectable Therapy Picture
Figure 5. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Application in 2019
Figure 6. Hospitals & Clinics Picture
Figure 7. Home Settings Picture
Figure 8. Ambulatory Surgical Centers (ASCs) Picture
Figure 9. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share in 2019
Figure 18. Global Top 10 Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 22. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Regions in 2018
Figure 23. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 24. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 29. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries in 2019
Figure 30. USA Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 31. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries in 2019
Figure 35. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 36. UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries in 2019
Figure 42. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 43. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 48. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries in 2019
Figure 49. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 54. UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Type (2015-2020)
Figure 58. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Type in 2019
Figure 59. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share Forecast by Type (2021-2025)
Figure 60. Global Oral Therapy Revenue Growth Rate (2015-2020)
Figure 61. Global Injectable Therapy Revenue Growth Rate (2015-2020)
Figure 62. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Application (2015-2020)
Figure 63. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Application in 2019
Figure 64. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share Forecast by Application (2021-2025)
Figure 65. Global Hospitals & Clinics Revenue Growth Rate (2015-2020)
Figure 66. Global Home Settings Revenue Growth Rate (2015-2020)
Figure 67. Global Ambulatory Surgical Centers (ASCs) Revenue Growth Rate (2015-2020)
Figure 68. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
Figure 72. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel

---